How has been the historical performance of the Fredun Pharma?

Answer:The historical performance of Fredun Pharma shows a consolidated net profit of 19.74 crore for the year ending March 2025, with total operating income recorded at 456.27 crore. The company incurred total expenditure of 401.36 crore, leading to an operating profit (PBDIT) of 54.91 crore. The profit before tax stood at 27.49 crore after accounting for interest expenses of 22.38 crore and depreciation of 5.04 crore. The earnings per share (EPS) for the same period was reported at 41.82, while the diluted EPS was slightly higher at 44.83. The operating profit margin, excluding other income, was 12.16%, and the profit after tax margin was 4.37%.

Breakdown:
In the fiscal year ending March 2025, Fredun Pharma achieved net sales of 456.27 crore, with no other operating income reported. The raw material cost was significant at 323.98 crore, contributing to a total expenditure of 401.36 crore, which included employee costs of 22.23 crore and other expenses of 31.54 crore. This resulted in an operating profit of 54.91 crore, leading to a profit before tax of 27.49 crore after deducting interest and depreciation. The net profit after tax was 19.74 crore, reflecting a PAT margin of 4.37%. The company maintained a strong equity capital of 4.72 crore and reserves of 136.68 crore, while the public shareholding was at 51.07%. Cash flow analysis indicates a net cash outflow of 2.00 crore for the year ending March 2024, with a closing cash and cash equivalent balance of 1.00 crore.